GW Pharmaceuticals Sittingbourne, Kent, UK
An all-new state-of-the-art manufacturing facility for GW Pharmaceuticals, a world leader in prescription cannabinoid medicines.
Corstorphine & Wright assisted long-standing client Trinity Investment Management and their occupier GW Pharmaceuticals to secure planning for an expansion of the Kent Science Park campus. The hybrid planning application sought to attain a detailed planning consent for and all-new state-of-the-art manufacturing facility for GW Pharmaceuticals and an outline consent for a further two research and development facilities that will be brought forward in the near future.
Corstorphine & Wright provided an articulated and modern facility fit for the operator whilst responding to visual impact constraints created by the surrounding green belt, residential properties and Area of Outstanding Natural Beauty.
The new facility will provide both additional growth capacity for the current products as well as flexibility for new products in the Research & Development pipeline.
GW Pharmaceuticals were established in 1998, with a mission to develop pharmaceutical products which address clear unmet medical needs. During this time GW Pharmaceuticals has become a world leader in prescription cannabinoid medicines. The Kent Science Park operations have existed since the conception of GW in the UK.
Through research, development and production, GW at Kent Science Park now supports the treatment of Multiple Sclerosis in adults as well as childhood onset Epilepsy focusing on Dravet Syndrome and Lennox-Gastaut Syndrome (LGS), two of the most difficult to treat epilepsy syndromes.